Phase I

**MDA-DM-96172, NCI-T96-0073** Phase I Study of Adenovirus p53 in Patients With Locally Advanced and Metastatic Bladder Cancer (summary last modified 08/1999)

Chairperson: Lance C. Pagliaro. Telephone: 713-792-2830. Lead organization: University of Texas-MD Anderson Cancer Center. Age range: 18 and over.

**UCCRC-8270, NCI-G97-1156** Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies (summary last modified 03/1998)


**MSKCC-97114, NCI-G98-1438** Phase I Study of Gemcitabine, Doxorubicin, and Paclitaxel Plus Carboplatin in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium and Impaired Renal Function (summary last modified 09/1998)


**MSKCC-97106, NCI-G97-1358** Phase I Study of Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy Following Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium (summary last modified 12/1999)


Phase I/II

**WVU-13707-OSP-97-092, NCI-V97-1114** Phase I/II Study of Intravesical Paclitaxel (Taxol) for the Treatment of Superficial Bladder Cancer (summary last modified 01/1998)


**RTOG-9906, RTOG-DEV-14321** Phase I/II Study of Radiotherapy With Concurrent Paclitaxel and Cisplatin Followed By Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy in Patients With Stage II or III Muscle Invasive Carcinoma of the Bladder Treated With Transurethral Tumor Resection (summary last modified 02/2000)

Chairperson: Donald S. Kaufman. Telephone: 617-726-8689. Lead organization: Radiation Ther-

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. A searchable PDQ Web site is also accessible at http://cancernet.nci.nih.gov/trialsrch.shtml
apy Oncology Group. Age range: not specified.

**MSKCC-97095, NCI-G97-1339**
Phase I/II Study of Sequential Doxorubicin/Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy for Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (summary last modified 12/1997)


**Phase II**

**ANTHRA-A9701/ID97-038, MDA-ID-97038**
Phase II Randomized Study of Peri-Operative Intravesical AD 32 Alone or Supplemented With BCG in Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer (summary last modified 11/1999)


**BRI-BL-2**
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Bladder Carcinoma (Summary last modified 10/1998)


**MSKCC-95031, NCI-V95-0743**
Phase II Study of CDDP/IFF/TAX in Advanced Urothelial Tumors (summary last modified 06/1998)


**EORTC-22971**
Phase II Study of Accelerated External Radiotherapy With Concurrent Fluorouracil and Cisplatin Following Transurethral Resection in Patients With Stage II or III Muscle Invasive Transitional Cell Carcinoma of the Bladder (summary last modified 12/1998)


**RPCI-DS-99-07, NCI-G99-1605**
Phase II Study of BCG Plus Interferon alfa 2b in Patients With Superficial Bladder Cancer (summary last modified 12/1999)


**E-2899**
Phase II Study of Docetaxel and Gemcitabine in Patients With Progressive Regional or Metastatic Carcinoma of the Urothelium (summary last modified 03/2000)


**UCCRC-10021, NCI-G00-1733**
Phase II Study of Docetaxel and Methotrexate Followed By Gemcitabine and Cisplatin in Patients With Stage IV Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium (summary last modified 04/2000)


**E-3897**
Phase II Study of Intravesical AD 32 in Patients With Recurrent or Refractory Papillary Transitional Cell Carcinoma and/or Carcinoma In Situ of the Bladder (summary last modified 05/2000)

MSKCC-96066, NCI-H97-1118 Phase II Study of Methotrexate/Vinblastine/Doxorubicin/Cisplatin Following Transurethral Resection of Bladder-Conﬁned Tumor in Stage II Transitional Cell Carcinoma of the Bladder (summary last modiﬁed 02/1997)


E-5899 Phase II Study of Paclitaxel and Gemcitabine in Patients With Advanced Transitional Cell Carcinoma of the Urothelium With Renal Insufﬁciency (summary last modiﬁed 05/2000)

E-3896 Phase II Study of Piriterexim in Refractory Urothelial Carcinoma (summary last modiﬁed 08/1998)

CAN-NCIC-IND128, SPRICAN-NCIC-IND128 Phase II Study of SCH 66336 in Patients With Previously Treated, Inoperable, Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder (summary last modiﬁed 04/2000)

EORTC-30971 Phase II Study of Thorough Transurethral Resection and Escalated Dose Methotrexate/Vinblastine/Doxorubicin/Cisplatin (M-VAC) in Patients With Transitional Cell Carcinoma of the Bladder (summary last modiﬁed 12/1998)

Phase III

MDA-ID-95236, NCI-G99-1621 Phase III Randomized Chemoprevention Study of Fenretinide in Patients With Superﬁcial Bladder Cancer (summary last modiﬁed 05/2000)

SWS-SAKK-06/98, EU-98075 Phase III Randomized Study Comparing Two BCG Strains in Patients With Ta or T1 Papillary Carcinoma of the Urinary Bladder or Carcinoma in Situ of the Urinary Bladder (summary last modiﬁed 10/1999)

ANTHRA-A9601 Phase III Randomized Study of AD 32 Following Transurethral Resection in Patients With Newly Diagnosed or Recurrent Superﬁcial Transitional Cell Carcinoma of the Bladder (summary last modiﬁed 02/2000)

SWOG-9809 Phase III Randomized Study of Ciproﬂoxacin vs Cephalexin in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder Treated With Transurethral Tumor Resection (summary last modiﬁed 04/2000)

NCCTG-979252, NCI-P98-0138 Phase III Randomized Study of High Dose Multivitamins as Chemoprevention of Stage 0 and I Resected Transitional Cell Carcinoma of the Bladder (summary last modiﬁed 04/2000)

E-4897 Phase III Randomized Study of Methotrexate, Vinblastine,
Doxorubicin, and Cisplatin (M-VAC) Versus Carboplatin and Paclitaxel for the Treatment of Advanced Carcinoma of the Urothelium (summary last modified 01/1999)


E-1897 Phase III Randomized Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Paclitaxel and Carboplatin as Post-operative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High Risk for Relapse (summary last modified 07/1999)


NYU-9852, NCI-G00-1715, LAC-USC-4B951 Phase III Randomized Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin vs Observation Alone Based on p53 Gene Status in Patients With Organ Confined Transitional Cell Carcinoma of the Bladder Who Have Undergone Radical Cystectomy and Bilateral Pelvic Lymphadenectomy (summary last modified 04/2000)


MRC-BS06, EU-91019 Phase III Randomized Trial of Adjuvant Radical Radiotherapy vs Observation or Intravesical Chemotherapy With BCG or MITO Following Endoscopic Resection of pT1 G3 Nx M0 Bladder Cancer (summary last modified 06/1995)


EORTC-30962 Phase III Study of Long Term vs Short Term Maintenance With Intravesical BCG at Either Standard Dose or 1/3 Dose in Patients With Intermediate and High Risk Ta or T1 Papillary Carcinoma of the Urinary Bladder (summary last modified 01/1999)


Legend for Abbreviations:

ANTHRA = Anthra Pharmaceuticals, Inc
BRI = Burzynski Research Institute
CAN-NCIC = National Cancer Institute of Canada
E = Eastern Cooperative Oncology Group
EORTC = European Organization for Research on Treatment of Cancer
EU = European Voluntary Protocol
LAC-USC = University of Southern California
MDA = MD Anderson Cancer Center
MRC = UK Medical Research Council
MSKCC = Memorial Sloan-Kettering Cancer Center
NCCTG = North Central Cancer Treatment Group
NCI = National Cancer Institute
NYU = New York University Cancer Center
RPCI = Roswell Park Cancer Institute
RTOG = Radiation Therapy Oncology Group
SPRI = Schering-Plough Research Institute
SWOG = Southwest Oncology Group
SW-SAKK = Swiss Group for Clinical Cancer Research
UCCRC = University of Chicago Cancer Research Center
WVU = West Virginia University Hospitals